TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use 1 effective method of contraception with all sexual partners during the study and for 14 days after the end of dosing.~* Male participants must be prepared to use 1 effective method of contraception with all sexual partners during the study during the study unless they had a prior vasectomy.~* Proven or likely PBC, as demonstrated by the participant presenting with at least 2 of the following 3 diagnostic factors:~* History of increased alkaline phosphatase (ALP) levels for at least 6 months;~* Positive antimitochondrial antibody titer (\>1:40 titer on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay) or PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive);~* Liver biopsy consistent with PBC~* Screening ALP level between 1.5 and 10 × upper limit of normal (ULN).~Exclusion Criteria:~* Administration of the following drugs at any time during the 3 months prior to screening for the study: ursodeoxycholic acid, colchicine, methotrexate, azathioprine, or systemic corticosteroids.~* Screening conjugated (direct) bilirubin \>2 × ULN.~* Screening alanine aminotransferase or aspartate aminotransferase \>5 × ULN.~* Screening serum creatinine \>133 micromoles/liter (1.5 mg/deciliter).~History or presence of hepatic decompensation (for example, variceal bleeds, encephalopathy, or poorly controlled ascites).~* History or presence of other concomitant liver diseases including hepatitis due to hepatitis B or C virus infection, primary sclerosing cholangitis, alcoholic liver disease, definite autoimmune liver disease or biopsy proven nonalcoholic steatohepatitis.~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DB OCA 10 mg (Type: EXPERIMENTAL): OCA 10 mg for 3 months during the DB phase.
- DB OCA 50 mg (Type: EXPERIMENTAL): OCA 50 mg for 3 months during the DB phase.
- DB OCA Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for 3 months during the DB phase.
- LTSE OCA Total (Type: EXPERIMENTAL): After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Preparation Using 2% Chlorhexidine Cloth For Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing shoulder surgery (open or arthroscopic)~Exclusion Criteria:~* Patient unwilling to comply with instructions~* Active infection in the operative extremity~* Documented allergic reaction to chlorhexidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
- 2% Chlorhexidine cloth (Type: EXPERIMENTAL): This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic stoke within 72 after onset, confirmed by MRI or CT.~* Age 35-75 years, inclusive.~* Patients with the first attack or patients with stroke history(modified Rankin Scale score 0-1).~* Clear signs of localization of nervous system, NIHSS score 4 to 22.~* Patient or proxy has signed informed consent.~Exclusion Criteria:~* Hemorrhage diseases according to head CT or MRI, such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, haemorrhage after cerebral infarction.~* Transient Ischemic Attack (TIA).~* Severe disturbance of consciousness: 1a of NIHSS score\>1 point; Difficulty in swallowing, unable to take oral capsules; any of 5a, 5b, 6a, 6b of NIHSS score\>2 point.~* Convinced of stroke caused by brain tumor, brain trauma, hemopathy, etc.~* Hemorrhagic tendency patients.~* Patients with endovascular treatment after the onset of stroke.~* Patients with dementia, severe Parkinson's disease, mental disorders, limb dysfunction caused by other diseases or other conditions that may affect the therapeutic efficacy.~* Uncontrolled hypertension (≥200 mmHg systolic or ≥110 mmHg diastolic) or hypotension (≤90 mmHg systolic or ≤60mmHg diastolic); severe hyperglycemia(blood glucose ≥400 mg/dl) or hypoglycemia( blood glucose≤50 mg/dl).~* Severe hepatic insufficiency defined as transaminase values \> 2x upper limit of normal; severe renal insufficiency defined as values serum creatinine\> 1.5x upper limit of normal; cardiac dysfunction or other serious systemic disease with life expectancy ≤3 months.~* Patients with concurrent malignancy or ongoing anti-tumor therapy.~* Patients with history of being allergic to the trial medicine.~* Pregnancy, breastfeeding or potential pregnancy.~* Within three months or currently participating in another investigational study.~* Any other condition that in the opinion of the investigator should preclude study participation.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tongxinluo capsule (Type: EXPERIMENTAL): Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
- placebo capsule (Type: PLACEBO_COMPARATOR): placebo capsule,4 granules,t.i.d. po,for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject (or subject's legally authorized representative) is willing and able to sign and date the Patient Consent Form (PCF) and authorization for access to and use of health information, if applicable~* Subject has been implanted with a Medtronic market released ICD or CRT-D device (US/Canada - Concerto®/Virtuoso® or newer model; AsiaPacific, Israel, Latin America - EnTrust™, InSync Sentry®, or Concerto®/Virtuoso® or newer model) within the past 30 days~* Subject has commercially released RA (if applicable), RV, and LV (if applicable) leads~Exclusion Criteria:~* Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the Medtronic Clinical Trial Leader

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Analysis cohort (Type: None): Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SAFE at Home: A Service to Provide Social Engagement to Community-Dwelling Persons With Dementia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
PWD Inclusion Criteria:~* 65+ years old~* speak and read conversational English~* diagnosed with dementia (any type)~PWD Exclusion Criteria:~-signs of rapid cognitive decline or physical deterioration over the last six months, as evidenced by medical records.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): SAFE at Home Intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with severe hemophilia A (baseline FVIII activity FVIII:C \<1%), determined by measurement at the time of screening (following a washout period of at least 72 h after their last FVIII treatment for standard half-life FVIII products or of 120 h for extended half-life FVIII products) or from reliable prior documentation (e.g. measurement in other clinical studies, result from approved clinical laboratory or diagnostic genetic testing).~* ≥150 exposure days with FVIII concentrate(s) (plasma-derived or recombinant) as supported by medical records.~* Body mass index (BMI) within the range 18 kg/m2 to 29.9 kg/m2 (inclusive).~Exclusion Criteria:~* Inability to stop FVIII treatment to complete a minimum of 72 h washout for standard half-life FVIII product or 120 h washout for extended half-life FVIII product~* Evidence of current or past inhibitor antibody~* History of any congenital or acquired coagulation disorders other than hemophilia A~* Platelet count \<75,000/mm3~* Human immunodeficiency virus (HIV) infection with a cluster of differentiation 4 (CD4+) lymphocyte count of \<200/mm3~* Abnormal renal function (serum creatinine \>2x the upper limit of the normal range \[ULN\])~* Active liver disease verified by medical history or persistently elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5x ULN or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio \>1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices~* Requirement of any pre-medication to tolerate FVIII treatment (e.g. anti-histamines)~* Prior treatment with immunomodulatory agents or chemotherapy within the last 3 months prior to study entry or requirement of treatment during the study. The following drugs are allowed: α interferon, PEG interferon, highly active anti-retroviral therapy for HIV, and/or a total of two courses of pulse treatment with steroid for a maximum of 7 days at 1 mg/kg or less

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAY94-9027 / Adynovi (Type: EXPERIMENTAL): Treatment sequence A-B with washout before each treatment
- Adynovi / BAY94-9027 (Type: EXPERIMENTAL): Treatment sequence B-A with washout before each treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dynamic Hyperinflation and Tiotropium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderately severe COPD patients age 40-85 yr with post 180ug albuterol FEV 1 between 60 and 79% predicted and FEV 1/FVC \< 70%.~* Smoking history \> 10 pack yr.~* Clinically stable X 6 weeks.~* No oxygen usage.~Exclusion Criteria:~* History of asthma~* Clinically unstable~* Any other significant medical problem precluding full cooperation for study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Tiotropium 18 µg capsule, bronchodilator (Type: ACTIVE_COMPARATOR): tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
- 2 (Type: PLACEBO_COMPARATOR): placebo 18ug tiotropium for 1 month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients histologically or cytologically diagnosed with advanced malignant solid tumors~* Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies~Exclusion Criteria:~* Central lung lesions involving major blood vessels~* Patients who have been treated with bevacizumab or other VEGFR inhibitor(s)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Open (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects 60 years of age or older, mentally competent, willing and able to give the written informed consent prior to study entry~Exclusion Criteria:~* Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD) that requires oxygen therapy, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure.~* Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine.~* History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine.~* Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Miswak and Miswak Extract on Oral Malodor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* the participants should report that they suffered from bad oral malodor~* organoleptic score of 2 or above~Exclusion Criteria:~* smoking~* current systemic diseases or medical treatment~* active caries or any faulty restorations~* acute sinusitis or oro-pharyngeal infection~* chronic periodontitis~* pregnancy~* breast feeding~* eating very spicy food~* use of antibiotic during the last two months before the start of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Miswak extract mouth wash (Type: EXPERIMENTAL): 50% mouthwash aqueous solution 5ml twice a day for 7 days
- Miswak sticks (Type: EXPERIMENTAL): Sticks twice a day for 7 days
- Chlorohexidine gluconate mouth wash (Type: ACTIVE_COMPARATOR): 0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be on a stable background Methotrexate (MTX) therapy prior to Day1/Randomization. Subjects must have taken MTX for at least 3 months at a dose ≥ 15 mg/week to a maximum weekly dose of ≤ 25 mg/week, and be at a stable dose for 4 weeks prior to randomization (Day 1). Methotrexate dose ≥ 15 mg/week that was not efficacious and that was decreased due to toxicity as low as 10 mg/week is allowed~* Inadequate response to NSAID and/or non-biologic DMARD~* Minimum of 3 swollen and 3 tender joints~* Active psoriatic skin lesions over minimum 3% body surface area~* high sensitivity C-reactive protein (hsCRP) ≥ 0.3 mg/dL~Exclusion Criteria:~* Previously received or currently receiving concomitant biologic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PBO: Placebo matching BMS-945429 (Type: PLACEBO_COMPARATOR): None
- BMS-945429 (25mg) (Type: EXPERIMENTAL): None
- BMS-945429 (100mg) (Type: EXPERIMENTAL): None
- BMS-945429 (200mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a diagnosis of T2DM and be currently treated with metformin and sulphonylurea~* Patients in the study must have a HbA1c between \>=7 and \<=10.5% and a fasting plasma glucose (FPG) \<300 mg/dL (16.7 mmol/L)~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* or a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings~* Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests~* Patient meets protocol criteria for diagnosis of IBS-C~* Patient demonstrates continued IBS-C through Pretreatment Period~* Patient is compliant with IVRS~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 290 μg Linaclotide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Healthy infants 6 -12 weeks old at Dose 1 with written informed consent.~Exclusion criteria:~* Allergic reaction to vaccine components;~* clinically significant history of chronic GI disease (uncorrected GI congenital malformation) or other serious medical condition per investigator, received vaccines or treatment prohibited by the protocol;~* immunocompromised.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete